论文部分内容阅读
目的评价胸腺肽在重度慢性阻塞性肺疾病(COPD)临床缓解期的应用疗效,指导今后的临床用药。方法回顾性分析2010年1月~2013年1月本院呼吸科门诊收治的60例重度COPD临床缓解期患者,除继续应用吸入激素及平喘药物改善临床症状外,上述患者随机分成两组,一组开始应用胸腺肽α11.6 mg,皮下注射,每周2次,连续应用12个月。另一组为随机对照组,不应用胸腺肽。结果应用胸腺肽组的患者与不应用胸腺肽组的患者相比,COPD急性发作需要住院的次数及住院天数明显减少,淋巴细胞亚群有明显改善。结论应用胸腺肽α1可以提高COPD临床缓解期患者的免疫力,减少COPD急性发作的次数,提高患者的生活质量,降低医疗费用。
Objective To evaluate the efficacy and safety of thymosin in the clinical remission of severe chronic obstructive pulmonary disease (COPD) and to guide clinical application in the future. Methods A retrospective analysis of 60 patients with severe COPD clinically treated in our Department of Respiratory Clinic from January 2010 to January 2013 was retrospectively analyzed. The patients were randomly divided into two groups except for continuous use of inhaled corticosteroids and antiasthmatic drugs to improve clinical symptoms. A group began to use thymosin α11.6 mg, subcutaneously twice a week for 12 consecutive months. The other group is a randomized control group, do not use thymosin. Results Compared with patients not using thymosin, patients with thymosin group had significantly fewer hospitalizations and days of hospital stay and a significant improvement of lymphocyte subsets in acute episodes of COPD. Conclusion The application of thymosin α1 can improve the immunity of COPD patients during clinical remission, reduce the number of acute exacerbations of COPD, improve the quality of life of patients and reduce the medical expenses.